AzTrials
AzTrials

CataractNCT03268746

Clinical Investigation of the Visual Outcomes and Safety of a Trifocal Intraocular Lens (IOL) in a Korean Population

A study testing AcrySof IQ PanOptix Multifocal IOL in people with Cataract and Presbyopia, run by Alcon Research at 4 sites in South Korea.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The purpose of this study is to confirm the effectiveness of the investigational lens in a Korean population, especially for visual performance, quality of vision, and subject satisfaction with the visual outcome, as well as the safety of the lens. This trial will be conducted in Korea. Read more about this study

Who is it for?
Ages 20 years and older
Conditions the study is for
Cataract, Presbyopia
What is being tested?
AcrySof IQ PanOptix Multifocal IOL
Type of treatment
Medical device
Could I receive a placebo?
No, everyone receives an active treatment
How many people
52 participants
Where
4 sitesSouth Korea
Study dates
9 Jan 2018to 30 Nov 2018
Phase
Interventional
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 20 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Requires cataract extraction in both eyes
  • Clear intraocular media other than cataracts in both eyes
  • Calculated lens power between +16.0 and +24.0 diopter (D)
  • Preoperative OR expected postoperative regular corneal astigmatism of < 1.00 D.

Who cannot join

  • Pregnant or lactating
  • Any clinically significant corneal abnormality, per the Investigator's expert medical opinion
  • Previous corneal transplant; previous ocular trauma; previous refractive surgery
  • History of, concurrent, or predisposition to retinal conditions, such as diabetic retinopathy, diabetic macular edema, or macular degeneration.

Trial locations and contacts

4 sites in 1 country.

South Korea4 sites
  • Alcon Investigative Site

    Seongnam-si, 13620

  • Alcon Investigative Site

    Seoul, 03722

  • Alcon Investigative Site

    Seoul, 05505

  • Alcon Investigative Site

    Seoul, 06351

Other trials in South Korea

About this study

Official title: Clinical Investigation of the Visual Outcomes and Safety After Bilateral Implantation of a Trifocal Presbyopia Correcting IOL in a Korean Population

The purpose of this study is to confirm the effectiveness of the investigational lens in a Korean population, especially for visual performance, quality of vision, and subject satisfaction with the visual outcome, as well as the safety of the lens. This trial will be conducted in Korea.

Read the detailed description

Both eyes of a subject must require cataract surgery to qualify for enrollment into this study. Subjects participating in the trial will attend a total of 9 study visits over a 4-5-month period. Of these 9 visits, 1 is preoperative, 2 are operative, and the remaining 6 are postoperative visits. Primary endpoint data will be collected at the Month 3 visit (Day 90-120 post second eye implantation). The second eye implantation will occur 2-30 days after the first implantation.

Conditions
Cataract, Presbyopia
Being tested
AcrySof IQ PanOptix Multifocal IOL
Keywords
Korea, Trifocal, PanOptix, Bilateral implantation, Cataract, Prospective, Single Arm, ACRYSOF, Model TFNT00
Medical subject headings
Cataract, Presbyopia

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • AcrySof IQ PanOptix Multifocal IOLDevice

    Also called Model TFNT00, AcrySof® IQ PanOptix™

    AcrySof IQ PanOptix Multifocal IOL Model TFNT00 for near, intermediate, and distance vision intended for long-term use over the lifetime of the cataract subject

Study groups in NCT03268746
Study groupRoleWhat they receive
Multifocal IOLExperimentalAcrySof IQ PanOptix Multifocal IOL Model TFNT00 implanted in the capsular bag following cataract removal. Both eyes will be implanted.
Receives: Device: AcrySof IQ PanOptix Multifocal IOL

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Binocular Defocus Curve at Month 3

    The defocus curve (an indicator of the expected range of vision with a presbyopia-correcting IOL) was tested binocularly (both eyes together) with the subject's best distance correction across full range varied from +2.0 diopter (D) to -5.0 D in 0.5 D increments. The visual acuity (VA) at each spherical power was measured in logarithm of the minimum angle of resolution (logMAR), with 0.1 logMAR increment corresponding to 5 letters, or 1 line, on an Early Treatment Diabetic Retinopathy Study (ETDRS) chart. A lower numeric value represents better VA. No formal statistical hypothesis testing was planned.

    Measured: Month 3 (Day 90-120 post second eye implantation)

Secondary outcomes (11)
  1. Binocular Defocus Curve at Month 1

    The defocus curve (an indicator of the expected range of vision with a presbyopia-correcting IOL) was tested binocularly (both eyes together) with the subject's best distance correction across full range varied from +2.0 diopter (D) to -5.0 D in 0.5 D increments. VA at each spherical power was measured in logMAR, with 0.1 logMAR increment corresponding to 5 letters, or 1 line, on an ETDRS chart. A lower numeric value represents better VA. No formal statistical hypothesis testing was planned.

    Measured: Month 1 (Day 30-60 post second eye implantation)

  2. Binocular Best Corrected Distance Visual Acuity (BCDVA) [4 Meters (m)]

    VA was tested binocularly under photopic conditions using the correction obtained from the manual manifest refraction and 100% contrast, ETDRS charts at a distance of 4 meters from the spectacle plane. VA was measured in logMAR, with 0.1 logMAR increment corresponding to 5 letters, or 1 line, on an ETDRS chart. A lower numeric value represented better VA. No formal statistical hypothesis testing was planned.

    Measured: Month 1 (Day 30-60 post second eye implantation) and Month 3 (Day 90-120 post second eye implantation)

  3. Monocular Uncorrected Distance Visual Acuity (UCDVA) (4 m)

    VA was tested monocularly (each eye separately) under photopic conditions without visual correction using 100% contrast ETDRS charts at a distance of 4 m from the eye, corresponding to a far distance for visual tasks. UCDVA was measured in logMAR, with 0.1 logMAR increment corresponding to 5 letters, or 1 line, on an ETDRS chart. Both eyes contributed to the analysis. A lower numeric value represented better VA. No formal statistical hypothesis testing was planned.

    Measured: Month 1 (Day 30-60 post second eye implantation) and Month 3 (Day 90-120 post second eye implantation)

  4. Monocular Uncorrected Intermediate Visual Acuity (UCIVA) [60 Centimeters (cm)]

    VA was tested monocularly under photopic conditions without visual correction using 100% contrast ETDRS charts at a distance of 60 cm from the eye, representative of intermediate distances for visual tasks. UCIVA was measured in logMAR, with 0.1 logMAR increment corresponding to 5 letters, or 1 line, on an ETDRS chart. Both eyes contributed to the analysis. A lower numeric value represented better VA. No formal statistical hypothesis testing was planned.

    Measured: Month 1 (Day 30-60 post second eye implantation) and Month 3 (Day 90-120 post second eye implantation)

  5. Monocular Uncorrected Near Visual Acuity (UCNVA) (40 cm)

    VA was tested monocularly under photopic conditions without visual correction using 100% contrast ETDRS charts at a distance of 40 cm from the eye, representative of near distances for visual tasks. UCNVA was measured in logMAR, with 0.1 logMAR increment corresponding to 5 letters, or 1 line, on an ETDRS chart. Both eyes contributed to the analysis. A lower numeric value represented better VA. No formal statistical hypothesis testing was planned.

    Measured: Month 1 (Day 30-60 post second eye implantation) and Month 3 (Day 90-120 post second eye implantation)

  6. Binocular Uncorrected Distance Visual Acuity (UCDVA) (4 m)

    VA was tested binocularly under photopic conditions without visual correction using 100% contrast ETDRS charts at a distance of 4 m from the eye, corresponding to a far distance for visual tasks. UCDVA was measured in logMAR, with 0.1 logMAR increment corresponding to 5 letters, or 1 line, on an ETDRS chart. A lower numeric value represented better VA. No formal statistical hypothesis testing was planned.

    Measured: Month 1 (Day 30-60 post second eye implantation) and Month 3 (Day 90-120 post second eye implantation)

  7. Binocular Uncorrected Intermediate Visual Acuity (UCIVA) (60 cm)

    VA was tested binocularly under photopic conditions without visual correction using 100% contrast ETDRS charts at a distance of 60 cm from the eye, representative of intermediate distances for visual tasks. UCIVA was measured in logMAR, with 0.1 logMAR increment corresponding to 5 letters, or 1 line, on an ETDRS chart. A lower numeric value represented better VA. No formal statistical hypothesis testing was planned.

    Measured: Month 1 (Day 30-60 post second eye implantation) and Month 3 (Day 90-120 post second eye implantation)

  8. Binocular Uncorrected Near Visual Acuity (UCNVA) (40 cm)

    VA was tested binocularly under photopic conditions without visual correction using 100% contrast ETDRS charts at a distance of 40 cm from the eye, representative of near distances for visual tasks. UCNVA was measured in logMAR, with 0.1 logMAR increment corresponding to 5 letters, or 1 line, on an ETDRS chart. A lower numeric value represented better VA. No formal statistical hypothesis testing was planned.

    Measured: Month 1 (Day 30-60 post second eye implantation) and Month 3 (Day 90-120 post second eye implantation)

  9. Binocular Photopic Best Corrected Contrast Sensitivity With Glare

    Contrast sensitivity (i.e., the ability to detect objects by distinguishing them from their background) was assessed binocularly under photopic conditions at a distance of 8 feet from the eye at spatial frequencies of 3, 6, 12, and 18 cycles per degree (cpd) using the Vector Vision CSV 1000-HGT with a glare source. A higher numeric value will represent better contrast sensitivity. No formal statistical hypothesis testing was planned.

    Measured: Month 3 (Day 90-120 post second eye implantation)

  10. Binocular Photopic Best Corrected Contrast Sensitivity Without Glare

    Contrast sensitivity (i.e., the ability to detect objects by distinguishing them from their background) was assessed binocularly under photopic conditions at a distance of 8 feet from the eye at spatial frequencies of 3, 6, 12, and 18 cpd using the Vector Vision CSV 1000-HGT without a glare source. A higher numeric value will represent better contrast sensitivity. No formal statistical hypothesis testing was planned.

    Measured: Month 3 (Day 90-120 post second eye implantation)

  11. Percentage of Subjects Who Responded to Subjective Symptoms Questions (SSQs)

    Subjects responded to 12 SSQs based on their experience during past 7 days for quality of vision and any change since cataract surgery as follows; Q1:How satisfied are you with your vision for seeing objects at near distance(ND)? Q2:How often do you wear eyeglasses or contact lenses for seeing objects at ND? Q3:How satisfied are you with your vision for seeing objects at intermediate distance(ID)? Q4:How often do you wear eyeglasses or contact lens for seeing objects at ID? Q5:How satisfied are you with your vision for seeing objects at distance(D)? Q6:How often do you wear eyeglasses or contact lens for seeing objects at D? Q7:How often do you experience halos? Q8:How severe were these halos? Q9:If you CURRENTLY DRIVE: how much difficulty do you have driving at night? Q10:If you DO NOT DRIVE at night, what is the reason? Q11:How satisfied are you with your cataract surgery result? Q12:Would you recommend cataract surgery and new lenses that were put into your eyes to other people?

    Measured: Preoperative and Month 3 (Day 90-120 post second eye implantation)

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted31 Aug 2017
  2. Study start9 Jan 2018
  3. Primary completion30 Nov 2018
  4. Study completion30 Nov 2018

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrolment
52 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03268746
Sponsor's protocol ID
ILH297-P004
Status last verified
Aug 2019
First submitted
30 Aug 2017
Last updated
25 Sep 2019
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
Individual data sharing
No

Publications

  • Kim TI, Chung TY, Kim MJ, Lee K, Hyon JY. Visual outcomes and safety after bilateral implantation of a trifocal presbyopia correcting intraocular lens in a Korean population: a prospective single-arm study. BMC Ophthalmol. 2020 Jul 15;20(1):288. doi: 10.1186/s12886-020-01549-z.

    PubMed 32669090

Questions about this trial

What is this clinical trial studying?

A study testing AcrySof IQ PanOptix Multifocal IOL in people with Cataract and Presbyopia, run by Alcon Research at 4 sites in South Korea.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 25 Sep 2019. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 4 sites in South Korea. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Yes. Results are posted in the registry (first posted 25 Sep 2019). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Binocular Defocus Curve at Month 3 (time frame: Month 3 (Day 90-120 post second eye implantation)). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT03268746, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 25 Sep 2019.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in
Clinical Trial NCT03268746 | AzTrials